In recent years, studies have elucidated some genetic changes in glioma, such as IDH1/23, TP534 and ATRX5 mutations, TERT promoter mutations6, MET-exon-14-skipping (METex14), PTPRZ1-MET (ZM) fusions, MET amplification7, MGMT promoter methylation8, and 1p/19q co-deletion9, which have been helpful in guiding the classification and treatment of glioma. This evidence concerns the gene IDH1 and central nervous system cancer.